Epidemiology
Epidemiological
and microbiological characterization of infections caused
by Staphylococcus aureus with reduced susceptibility to
vancomycin, U.S., 1997-2001.
Clin Infec Dis 2003 Leave
CDC
Public
Health Dispatch: Vancomycin-Resistant Staphylococcus aureus
- Pennsylvania, 2002 MMWR
October 2002
Staphylococcus
aureus Resistant to Vancomycin MMWR
July 2002
Vancomycin-intermediate
and -resistant Staphylococcus aureus: what the infectious
disease specialist needs to know. Clin
Infect Dis 2001 Leave CDC
Emergence
of vancomycin resistance in Staphylococcus aureus. N
Engl J Med 1999 Leave
CDC
Vancomycin-Intermediate
Staphylococcus aureus in a Home Health-Care Patient
EID Journal 2001
Staphylococcus
aureus with Reduced Susceptibility to Vancomycin---Illinois,
1999. MMWR 2000
Staphylococcus
aureus with Reduced Susceptibility to Vancomycin Isolated
from a Patient with Fatal Bacteremia.
EID Journal 1999
Update:
Staphylococcus aureus with Reduced Susceptibility
to Vancomycin - U.S., 1997.
MMWR 1997
PDF (265KB)
Staphylococcus aureus
with Reduced Susceptibility to Vancomycin -
U.S. 1997. MMWR 1997
PDF (273KB)
Reduced Susceptibility
of Staphylococcus aureus to Vancomycin -
Japan 1996. MMWR 1997
PDF (86KB)
Laboratory
Cui L., et al. Cell
Wall Thickening Is a Common Feature of Vancomycin Resistance
in Staphylococcus aureus J Clin Microbiol. 2003;41:
5-14.
Increasing
resistance vancomycin and other glycopeptides in Staphylococcus
aureus. EID Journal 2001
Laboratory
Capacity to Detect Antimicrobial Resistance,
1998. MMWR 2000
Tenover FC, Lancaster MV, Hill BC, et
al. Characterization of staphylococci
with reduced susceptibilities to vancomycin and other glycopeptides.
J Clin Microbiol 1998;36:1020-7. [Erratum, J Clin Microbiol;36:2167.]
|